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ABSTRAK
Ustekinumab adalah agen biologi yang berkesan untuk rawatan kulit psoriasis 
dengan menyasarkan molekul interleukin 12 dan 23. Namun begitu ada beberapa 
halangan ketika penggunaannya seperti kegagalan sekunder dan juga peristiwa 
paradoks. Penyakit juga didapati kembali menyerang selepas terapi dihentikan. 
Kajian kohort retrospektif telah dilakukan ke atas pesakit kulit kronik psoriasis 
yang telah menerima ustekinumab di antara tahun 2013 ke 2018 di Pusat 
Perubatan Universiti Kebangsaan Malaysia (PPUKM). Demografi, ciri-ciri klinikal, 
keberkesanan rawatan, komplikasi, kadar dan corak penyakit berulang dikaji 
melalui rekod-rekod pesakit. Enam (75%) pesakit adalah lelaki. Enam (75%) pesakit 
ini tidak pernah menerima agen biologi sebelum ini. Usia median pesakit adalah 
41.5 tahun (IQR 26.8-48.3), tempoh median penyakit ialah 16.5 tahun (IQR 6.5-
23.0). Tempoh median untuk mencapai kadar 75% pengurangan penyakit (PAS 
I75) adalah 16 minggu. PASI75 pada minggu ke 12 dicapai oleh 37.5% pesakit 
manakala tempoh median untuk mencapai sekurang-kurangnya PASI75 adalah 16 
minggu. Tempoh median keseluruhan rawatan adalah selama 102 minggu. Semua 
pesakit berjaya dirawat. Dua (25%) pesakit mengalami kegagalan sekunder. Seorang 
(12.5%) pesakit mendapat peristiwa paradoks dengan tumbuhnya fenomena 
nanah dan plak di kulit semasa rawatan. Tempoh median untuk penyakit berulang 
adalah 40 minggu. Semua pesakit kecuali seorang memerlukan rawatan biologi 
untuk penyakit berulang. Ustekinumab berkesan untuk semua pesakit. Kejayaan 
rawatan diperolehi 4 minggu selepas piawai yang dijangkakan. Kohort ini telah 
merekodkan kegagalan sekunder dan fenomena paradoks yang jarang berlaku. 
Penyakit didapati akan berulang dan corak psoriasis yang berbeza ditemui selepas 
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rawatan dihentikan.
Kata kunci: agen biologi, psoriasis, ustekinumab
ABSTRACT
Ustekinumab is an anti-IL12/23 biologic agent used for treatment of psoriasis with 
excellent efficacy. However, there are therapeutic obstacles such as secondary 
failure and paradoxical event. Disease relapse upon discontinuation of therapy is 
common. A case series was performed on patients with chronic plaque psoriasis 
who received ustekinumab between 2013 to 2018 at a tertiary referral centre. 
Demographics, clinical characteristics, duration of therapy, efficacy, treatment 
complications, rate and pattern of relapses were determined from the patients’ 
medical records. Out of 8 patients, 6 (75%) patients were males. There were 6 
(75%) biologic-naïve patients. Median age was 41.5 years (IQR26.8-48.3), median 
duration of psoriasis was 16.5 years (IQR6.5-23.0). Median duration to achieve 
Psoriasis Activity and Severity Index (PASI)75 was 16 weeks and median total 
duration of treatment was 102 weeks. All patients achieved treatment success. 
PASI75 at week 12 was achieved by 37.5%, a median of 16 weeks was required 
to achieve at least PASI 75 but 6 (75%) attained PASI 90 by then. One patient 
(12.5%) developed paradoxical event with pustular and plaques.  Secondary failure 
occurred in 2 (25%) patients. All patients relapsed after treatment discontinuation, 
relapse occurred at median of 40 weeks. Most (71%) developed plaques on 
relapse but 25% developed plaques and pustules. All but one patient required 
further biological agent for treatment of relapse. Ustekinumab was efficacious in 
all patients. Treatment success was achieved slightly later than standard duration. 
The rare occurrences of secondary failure and paradoxical were observed. Relapse 
was inevitable, new onset pustular eruptions featured in relapses.  
Keywords: biologics, psoriasis, ustekinumab
2008; Smith et al. 2017) The effect of 
the disease on patients’ quality of life 
is well documented (De Korte et al. 
2004).
 Biological agents marked an 
important milestone in psoriasis 
therapy. Their  efficacies  are 
comparable or superior than 
conventional systemic therapies, 
with very good safety profiles. 
INTRODUCTION 
Psoriasis is a chronic immune-
mediated disease with cutaneous and 
joint involvement that affect 0.91- 
8.5% of the world’s population (Parisi 
et al. 2013). Cardiovascular disease and 
the metabolic syndrome are common 
and important systemic associations 
(Choon et al. 2014; Kimball et al. 
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Conventional systemic therapies 
such as methotrexate, acitretin and 
cyclosporine are limited by various 
serious adverse effects including bone 
marrow suppression, dyslipidaemia, 
liver cirrhosis, pulmonary fibrosis, 
hypertension and renal impairment 
(Choon et al. 2014; Kimball et al. 
2008). Indications for biological agents 
in chronic plaque psoriasis are patients 
with severe disease that have failed or 
are contraindicated for systemic agents 
(Choon et al. 2014; Smith et al. 2017), 
or diseases with significant impact 
on physical, psychological, or social 
functioning (Smith et al. 2017). 
 Ustekinumab is a fully human 
IgG monoclonal antibody against 
interleukin (IL)-12 and IL-23 (Benson et 
al. 2011). Ustekinumab is among the 
first line of biologics recommended 
in many chronic plaque psoriasis 
guidelines (Choon et al. 2014; Menter 
et al. 2011; Ohtsuki et al. 2013; Smith 
et al. 2017). Psoriasis Area and Severity 
Index or PASI is accepted worldwide 
as a tool to assess severity of plaque 
psoriasis by assessing three domains 
clinically which include thickness 
of plaques, erythema and scale 
thickness (Chalmers 2015). Sixty to 
seventy percent of patients achieved 
target response by 12 weeks (Menter 
et al. 2011; Ohtsuki et al. 2013; 
Smith et al. 2017). Adverse events 
including injection site reactions were 
comparable to placebo (Leonardi 
et al. 2008). While the efficacy and 
safety of biological agents including 
ustekinumab are well documented, 
other therapeutic issues like secondary 
failure, paradoxical event and relapse 
are limited to case reports and case 
series. Biological agents are reserved 
for patients with severe psoriasis and 
complicated management history in 
our clinical setting as usage is limited 
by the high cost of these medications. 
We report our experience using 
ustekinumab for psoriasis in a case 
series involving 8 patients treated at 
a tertiary referral centre in central 
Malaysia to highlight therapeutic 
obstacles of secondary failures, 
paradoxical events and relapses. 
MATERIALS AND METHODS
A retrospective case series was 
performed. We reviewed the medical 
records of patients who received 
ustekinumab for chronic plaque 
psoriasis between 2013 to 2017 
in Dermatology Clinic, Universiti 
Kebangsaan Malaysia Medical Centre 
(UKMMC). Data on demography, 
clinical characteristics, duration of 
ustekinumab therapy, rate of disease 
clearance, rate of relapse and pattern 
of relapse were recorded. Treatment 
success was defined as achieving 
PASI75 (at least 75% reduction of 
PASI from baseline) at week 12 
(Menter et al. 2011; Smith et al. 2017). 
PASI is well recognised psoriasis 
severity assessment tool. Severity of 
plaque psoriasis is determined by 
clinical assessment of three domains; 
thickness of  the plaques, erythema 
and scale (Chalmers 2015). Minimal 
response criteria was defined as PASI 
at least 50 from baseline (Smith et 
al. 2017). Relapse meant loss of PASI 
after stopping treatment (Menter et 
al. 2011). Time to relapse was defined 
as time to lose PASI50 (Menter et al. 
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2011). Secondary failure occurred 
when PASI50 was initially achieved 
PASI50 but the response was lost with 
time and ongoing treatment (Smith et 
al. 2017). 
RESULTS
Eight patients were treated with 
ustekinumab during the study period. 
Six were males (75%), 2 females 
(25%) with median age of 41 years  
(IQR26.8-48.3). Median duration of 
psoriasis was 16.5 years (IQR6.5-23.0). 
Ustekinumab dose was prescribed 
according to standard dosing protocol 
of subcutaneous 45 mg subcutaneous 
injections at week 0, 1, and 4, followed 
by every 12 weeks. The dose for one 
patient was increased to 90 mg starting 
from week 12 as he weighed almost 
100 kgs with severe erythrodermic 
psoriasis. Six (75%) patients had 
chronic plaque psoriasis, 25% have 
pustular psoriasis while 2 (25%) 
had psoriatic arthropathy. Six (75%) 
patients were biologic naïve and two 
(25%) had psoriatic arthropathy.
Patient 1 
A 50-year-old male with 20 years 
history of chronic plaque psoriasis. 
Narrowband UVB phototherapy 
(NBUVB) failed to achieve satisfactory 
response. Other previous treatments 
included ciclosporin (completed 1 
year), methotrexate with cumulative 
dose approaching 4 gm and acitretin. 
Baseline PASI was 14.8. PASI90 was 
achieved by week 16 and his total 
treatment duration was 105 weeks. 
Psoriasis relapsed 40 weeks post 
ustekinumab, with plaques and 
minimal pustules. 
Patient 2 
A 46-year-old male had chronic 
plaque psoriasis for 25 years. Acitretin 
and methotrexate (cumulative dose 1.5 
g) was complicated by transaminitis. 
He had received ustekinumab for a 
total of 52 weeks with good response. 
The second course of ustekinumab 
was commenced 40 weeks after 
discontinuation of the first course 
with baseline PASI of 15 and DLQI  of 
18. Psoriasis was well controlled by 
12 weeks. However, he developed 
secondary failure at 52 weeks  
with PASI of 12.2 and DLQI of 16. 
Methotrexate was added for combined 
therapy without much improvement. 
Ustekinumab was later switched to 
secukinumab. 
Patient 3 
A 38-year-old male with chronic plaque 
psoriasis and psoriatic arthropathy 
(PsA) of 4 years duration. He had been 
treated with few biological agents 
including etanercept, adalimumab 
and ustekinumab with good response. 
However, treatment were interrupted 
due to limited funding. Ciclosporin 
caused hypertension, methotrexate 
caused hepatitis and he failed NBUVB. 
His baseline PASI was 54.6 and DLQI 
was 24. PASI75 was achieved after 4 
weeks of ustekinumab therapy. PASI90 
was achieved with quiescent PsA at 52 
weeks. Ustekinumab was maintained 
for 2 years. Chronic plaque psoriasis 
and PsA flared 26 weeks off therapy. 
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Ustekinumab was then restarted.
Patient 4 
A 29-year-old male had 14 years 
history of chronic plaque psoriasis. 
Methotrexate caused transaminitis. His 
baseline PASI was 70.5. PASI90 was 
achieved after 17 weeks of ustekinumab 
therapy which was maintained for 41 
weeks. Relapse with plaque psoriasis 
occurred after 65 weeks  of stopping 
ustekinumab. He was subsequently 
treated with secukinumab. 
Patient 5 
A 44-year-old male had guttate and 
pustular psoriasis for 4 years. He 
experienced acitretin induced hepatitis 
and periungual granuloma. There 
was poor response to methotrexate. 
He achieved PASI75 at week 42 
with baseline PASI of 65.3 following 
ustekinumab therapy. Ustekinumab 
was continued for 123 weeks. Relapsed 
of psoriasis occurred at week 66 week.
Patient 6 
A 26-year-old female developed 
chronic plaque psoriasis at the age 
of 8 years. She had methotrexate 
induced lung fibrosis and 
cyclosporine induced hypertension 
and hypercholesterolaemia. Her 
baseline PASI was 14.3. She achieved 
PASI100 at week 16. Unfortunately, 
she developed paradoxical pustular 
psoriasis with 1% body surface area 
covered with pustules and plaques at 
week 24 week. There were no other 
identifiable triggers for the eruptions. 
She responded well to topical 
corticosteroid. She received 77 weeks 
of ustekinumab. Plaques reappeared 




A 49-year-old female had psoriasis for 
the past 24 years.  She had pustular 
psoriasis which later developed into 
severe chronic plaque with psoriatic 
arthropathy. NBUVB was ineffective 
with poor response to acitretin, and 
methotrexate caused bicytopenia. 
Baseline PASI was 20.3. PASI75 was 
achieved after 4 weeks of ustekinumab. 
She developed secondary failure at 
week 44 despite being a biologic naïve 
patient. She is now on secukinumab.
Patient 8 
A 21-year-old male had concurrent 
chronic plaque psoriasis and atopic 
eczema of 15 years. He was treated 
with ciclopsorin for 2 years, his eczema 
went into remission but he developed 
severe psoriasis flare. Methotrexate 
therapy was complicated by 
transaminitis. Prior to ustekinumab, his 
baseline PASI was 22.4. He achieved 
PASI90 at week 16. He was still on 
ustekinumab 12 weekly with duration 
of treatment of 140 weeks at the time 
of data collection. Table 1 summarised 
the patients’ demographic and clinical 
characteristics.   
 PASI75 or treatment success was 
achieved at week 12 by 3 (37.5%) of 
our patients. A median of 16 weeks 
therapy was required to achieve at 
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least PASI75 however 6 (75%) patients 
showed excellent response where 
PASI90 was attained. The median total 
duration of treatment were 102 weeks 
with relapse occurring at a median 
of 40 weeks. All patients relapsed 
and required re-commencement of 
a biological agent except for patient 
1 whom was treated with acitretin. 
Disease duration (r=0.47, p=0.24), 
PASI at week 0 (r=-0.24, p=0.57), and 
treatment duration (r=0.36, p=0.43) 
were not identified as risk factors for 
relapse. Interestingly 2 (25%) patients 
with chronic plaque psoriasis relapsed 
with development of both plaque and 
pustular types of psoriasis. Secondary 
failure was seen in 2 (25%) patients 
whilst on ustekinumab at week 52 
and 44 weeks,  the latter patient was 
a biologic-naïve patient. Paradoxical 
event with mild pustules and plaques 
was observed in 1 (12.5%) patient. It 
was successfully controlled with topical 
corticosteroids without requiring 
discontinuation of ustekinumab. There 
were no other major or minor adverse 
events experienced by our patients. 
Table 2 showed an overview of the 
therapeutic regimes, response, relapse 
and treatment following ustekinumab 






















3 38/M/I Ps Yes 4 Dyslipidaemia 
Hypertension 




4 29/M/M Ps No 14 Obesity 
Dyslipidaemia
Yes Yes MTX
5 44/M/M Pustular 
→ Ps









7 49/F/C Pustular 
→ Ps












Photo=pthototherapt; Ps=psoriasis; PsA=psoriatic arthritis' IHD=ischaemic heart disease' T2DM=type II 
diabetes mellitus; CsA= cyclosporine; MTX= methotrexate
Table 1: Demographic and clinical characteristics of the patients.
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DISCUSSION
All of our patients showed improvement 
with ustekinumab therapy. However, 
PASI75 achieved at our centre by 
week 12 were lower if compared to at 
least 59.5% as reported by landmark 
trials (Griffiths et al. 2010; Igarashi et 
al. 2012; Leonardi et al. 2008; Kim et 
al. 2008; Tsai et al. 2011). Instead our 
PASI75 or higher were achieved by 
median of week 16. The delay may 
be due to severe disease (median PASI 
21.4, IQR14.9-62.6 at baseline) and 
most patients had difficult to treat and 
recalcitrant psoriasis with failures to 
other systemic therapies. 
 Psoriasis relapses were observed 
in all our patients following 
discontinuation of ustekinumab. 
Disease duration, psoriasis severity 
and ustekinumab treatment duration 
were not multiple co-morbidities is a 
factor that may have contributed to 
higher risk of relapse. All patients have 
dyslipidaemia, most had concomitant 
hypertension (5, 62.5%) and fatty liver 
(3, 37.5%). These diseases contribute 
to systemic inflammation which 
affects psoriasis therapy (Kimball et 
al. 2008). A non-significant longer 
durability of therapeutic effect has 
been documented with longer 
treatment duration (Ko et al. 2009; 
Tsai et al. 2011). Our patients received 
longer total duration of treatment, 
and relapses occurred later compared 
to ACCEPT (Griffiths et al. 2010) with 
total treatment duration of 52 weeks 
and relapses recorded at 18 weeks. 
Relapses at 22 weeks after 40 weeks of  





45 mg at 




















Rx  post 
relapse




2 15 Yes Yes 12 12 77 Secondary failure 
week 52
Secukinumab
3 54.6 Yes Yes 4 50 120 26 Plaque Ustekinumab 
4 70.5 Yes No 17 17 41 65 Plaque Secukinumab
5 65.3 45 mg x2, 
90 mg 12 
weekly
No 42 52 123 66 Plaque Secukinumab




7 20.3 Yes Yes 4 16 102 Secondary failure 
week 44
Secukinumab
8 22.4 Yes No 16 16 Treatment continued
GPP=generalised pustular psoriasis
Table 2: Therapeutic regimes, response, relapse and treatment following discontinuation 
of ustekinumab.
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Kamaria et al. (2018). All of our patients 
except one required re-treatment with 
biological agent following their relapse. 
 We were not able to find data on 
type of relapse in literature. Most 
of our patients developed plaques 
but interestingly a quarter of them 
developed pustules for the first time. 
Systemic corticosteroid withdrawal is 
well recognised to precipitate pustular 
psoriasis. Chronic plaque psoriasis 
transformed to pustular type due to 
unstable, active inflammatory process 
caused by abrupt corticosteroid 
dose reduction or discontinuation 
(Benjegerdes et al. 2016). However, 
the pustules appeared much later than 
that induced by corticosteroids which 
typically occurred between 4-8 weeks.
 Secondary failure was observed 
in our biologic naïve and biologic 
experienced patients. Secondary 
failure has been associated with 
development of antidrug antibody 
(ADA) with a prevalence of 3.8-6% 
(Hsu et al. 2014). Anti ustekinumab 
antibody (AUA) were found in patients 
with minimal response at 36-52 weeks 
of therapy (Chiu et al. 2014; Hsu et 
al. 2014; Kim et al. 2008). We were 
unable to test for AUA and serum 
ustekinumab due to limited resources. 
Anti-nuclear antibody (ANA) positivity 
has also been associated with higher 
risk of secondary failures (Griffiths et 
al. 2010). ANA were negative both 
pre and post treatment in our patients. 
Concomitant use of methotrexate 
reduced the risk of secondary failure 
while on anti -tumour necrosis factor 
α agents (anti-TNFα) (Hanauer et 
al. 2004; Toussirot & Aubin 2016). 
However, this is not the case for 
ustekinumab as its pharmacokinetics 
are unaffected by simultaneous use of 
methotrexate (Harrison et al. 2009).
 Our case series captured occurrence 
of paradoxical event which is rarely 
reported with ustekinumab, despite 
our small number patients. Paradoxical 
event is more commonly associated 
with anti-TNFαα therapy in patients 
with rheumatoid arthritis (Hanauer 
et al. 2004; Toussirot & Aubin 2016), 
chronic plaque psoriasis, ankylosing 
spondylitis and inflammatory bowel 
disease (Harrison et al. 2009). The 
cutaneous eruptions reported were 
mainly pustular but includes chronic 
plaques and guttate psoriasis (Toussirot 
& Aubin 2016). TNF-α inhibitors 
induced or exacerbate psoriasis in 
127 patients, where palmo-plantar  
pustular psoriasis accounted for 40.5% 
while plaque-type psoriasis occurred 
in 33.1% (Ko et al. 2009). Pustules 
localised to the legs developed after 
9 days of ustekinumab, treatment was 
changed to golimumab (Dai & Chen 
2018). Both plaques and pustules 
occurred after 10 and 4 weeks of 
treatment respectively in another 2 
patients (Caca-Biljanovska et al. 2013; 
Hay & Pan 2014). Topical treatment 
was successful without the need 
to withdraw ustekinumab (Caca-
Biljanovska et al. 2013) while a more 
widespread disease required switching 
of the biologic agent to adalimumab 
(Hay & Pan 2014). Palmo-plantar 
eruptions occurred after 6 weeks of 
ustekinumab treatment that required 
a change of therapy to cyclosporine 
in another patient (Suh et al. 2018). 
Based upon the experiences of 
all of these authors, therapy and 
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decision to discontinue ustekinumab 
depended on the clinical severity of 
the paradoxical event while the choice 
of alternative therapy varies. Table 
3 summarised the characteristics of 
paradoxical events reported in the 
literature and subsequent management 
of the patients. The postulated 
pathophysiology of paradoxical 
events are chemokine disequilibrium 
and gene polymorphism (Seneschal 
et al. 2009). Inhibition of IL-23 may 
indirectly cause increase in IFN α that 
promote T-cell activation indirectly 
via myeloid dendritic cell, or directly 
through IFNαα sensitive T cells (Chan 
et al. 2006; Nestle & Gilliet 2005). 
IFNαα also stimulates expression of 
chemokine T-cell receptors leading 
to aberrant expression of T-cells and 
neutrophils causing the paradoxical 
eruption (Elliott et al. 2009; Friedrich 
et al. 2014). IL36 receptor antagonist 
mutation is thought to be involved 
as it is well recognised in inducing 
generalised pustular psoriasis (Wang et 
al. 2016). Interpretation of our results are 
limited by the small number of patients 
and should not be generalised. The 
subjects were a group of patients with 
severe psoriasis, multiple comorbidities 
and complicated management history. 
However, they represent the typical 
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Table 3: Summaries of  paradoxical events compared with current literatures
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agents in our country.    
CONCLUSION
Ustekinumab was efficacious, PASI75 
as the therapeutic target was achieved 
but treatment success took slightly 
longer. All patients failed to maintain 
disease remission after discontinuation 
of ustekinumab therapy, relapse was 
rapid and almost all patients required 
further biological therapy. Pustular 
relapse was observed in patients 
without history of pustular lesions. 
Secondary failures and paradoxical 
event were captured in our small case 
series despite its rarity.   
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